Drug Trial Radar · NCT05018702
ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases
Last checked: Nov 19, 2026Latest source record: Jun 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
32
Planned (sponsor's estimate)
Start
Jul 14, 2021
Primary completion
Dec 30, 2022
Study completion Jun 30, 2023
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients whose Disease is resistant or refractory to Tyrosine kinase inhibitors (TKI).
Conditions
- HER2-positive, Metastatic Breast Cancer
Interventions
ARX788Drug
1.5 mg/kg IV infusion on Day 1 of each 21-day treatment cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Central nervous system (CNS) clinical benefit rate (CBR)Time frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.